2025年12月11日,诺诚健华自主研发的新一代TRK抑制剂佐来曲替尼(ICP-723)通过NMPA优先审评审批程序附条件获批上市,适用于确诊携带NTRK融合基因且符合特定条件的成人及12岁以上青少年实体瘤患者,是中国首款自主研发的新一代TRK抑制剂。该药作为第二代TRKi,能抑制多种靶点及耐药性突变,克服第一代耐药问题,且被纳入“星光计划”。临床数据显示,其疗效突出,起效快,疗效持续时间长,最长...
Source Link2025年12月11日,诺诚健华自主研发的新一代TRK抑制剂佐来曲替尼(ICP-723)通过NMPA优先审评审批程序附条件获批上市,适用于确诊携带NTRK融合基因且符合特定条件的成人及12岁以上青少年实体瘤患者,是中国首款自主研发的新一代TRK抑制剂。该药作为第二代TRKi,能抑制多种靶点及耐药性突变,克服第一代耐药问题,且被纳入“星光计划”。临床数据显示,其疗效突出,起效快,疗效持续时间长,最长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.